# Kenvue **Source:** https://geo.sig.ai/brands/kenvue **Vertical:** Consumer Goods **Subcategory:** Enterprise **Tier:** Leader **Website:** kenvue.com **Last Updated:** 2026-04-14 ## Summary Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G. ## Company Overview Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J). Kenvue's consumer health brand portfolio model creates competitive advantages through the household name recognition and shelf-space permanence of trusted OTC health brands: Tylenol's #1 position in the US acetaminophen pain relief category (held for decades despite FDA-mandated labeling changes and generic competition) reflects consumer trust in a brand associated with safe, effective fever and pain management for children and adults — with pediatricians recommending Tylenol by brand name to parents, creating a healthcare professional endorsement that private label acetaminophen cannot easily replicate. Band-Aid's adhesive bandage category dominance (Band-Aid accounting for 60%+ of US adhesive bandage sales as a genericized trademark — where "Band-Aid" means "adhesive bandage" in American English — creating the market where being named Band-Aid is itself the competitive advantage) demonstrates how Kenvue's brands have become synonymous with their product categories. Listerine's antiseptic mouthwash positioning (clinical efficacy claims backed by FDA monograph compliance — Listerine is the only mouthwash with FDA-approved oral health claims for gingivitis reduction) sustains premium pricing versus private label mouthwashes in drugstore and grocery OTC aisles. In 2025, Kenvue competes in over-the-counter consumer health, skin care, and oral care against Haleon (LON: HLN, Advil, Sensodyne, Theraflu, Chapstick — UK consumer health spun off from GSK and Pfizer), Procter & Gamble (NYSE: PG, Crest, Vicks, Metamucil, Pepto-Bismol), and Bayer AG (ETR: BAYN, Claritin, Alka-Seltzer, Aspirin consumer health portfolio) for retail pharmacy shelf space, consumer brand preference in OTC health categories, and digital health commerce channel growth. The talc litigation exposure (Kenvue assumed liability for talc claims related to Johnson's Baby Powder from J&J at the spinoff — ongoing mass litigation alleging talc caused mesothelioma and ovarian cancer) represents the most significant legal risk for Kenvue independent of its operating performance. Neutrogena's competition from affordable Korean beauty (CeraVe, La Roche-Posay, and drugstore skincare brands gaining market share through dermatologist recommendations) challenges Neutrogena's premium dermatologist-recommended skincare positioning. The 2025 strategy focuses on Tylenol and Listerine brand equity reinforcement through digital and TV advertising, Neutrogena skin health positioning differentiation from competitive skincare brands, and talc litigation resolution management. ## Frequently Asked Questions ### What is Kenvue? Kenvue is a global consumer health company that owns iconic brands including Tylenol, Listerine, Neutrogena, Band-Aid, Aveeno, and Johnson's Baby. The company was spun off from Johnson & Johnson in May 2023 and operates in over 100 countries, serving billions of consumers with science-backed everyday care products. ### When was Kenvue founded? Kenvue became an independent public company on May 4, 2023, through an IPO that raised $3.8 billion. However, the company's heritage traces back to 1886 when the Johnson brothers founded Johnson & Johnson in New Brunswick, New Jersey, giving Kenvue over 135 years of consumer healthcare expertise. ### Where is Kenvue headquartered? Kenvue is headquartered in Summit, New Jersey, USA. The company operates globally with approximately 22,000 employees distributed across North America (25%), EMEA (28%), APAC (28%), and LATAM (19%), serving consumers in over 100 countries. ### What does Kenvue do? Kenvue develops, manufactures, and markets consumer health products across three segments: Self Care (pain relief, allergy, and cold products like Tylenol and Benadryl), Skin Health and Beauty (dermatologist-recommended skincare including Neutrogena and Aveeno), and Essential Health (oral care, baby products, and wound care including Listerine, Johnson's Baby, and Band-Aid). ### Who are Kenvue's customers? Kenvue serves billions of consumers worldwide through retail pharmacies, mass merchandisers, e-commerce channels, and healthcare professional recommendations. The company's products appeal to families seeking trusted baby care, individuals managing pain or allergies, and consumers looking for dermatologist-recommended skincare solutions. ### What is Kenvue's relationship to Johnson & Johnson? Kenvue was Johnson & Johnson's consumer health division until it was spun off as an independent public company in May 2023. While Kenvue inherited J&J's consumer health brands and 137-year heritage, it now operates as a completely separate entity focused exclusively on consumer health products. ### Is Kimberly-Clark acquiring Kenvue? Yes, Kimberly-Clark announced in November 2025 that it will acquire Kenvue for a total enterprise value of $48.7 billion. The transaction, which will create a $32 billion global health and wellness leader with 10 billion-dollar brands, is expected to close in the second half of 2026 pending regulatory approvals. ### What are Kenvue's main brands? Kenvue's portfolio includes Tylenol (pain relief), Listerine (oral care), Neutrogena and Aveeno (skincare), Band-Aid (wound care), Johnson's Baby (baby care), Benadryl (allergy relief), Zyrtec (allergy), and numerous other trusted consumer health brands serving various health and wellness needs. ### How much revenue does Kenvue generate? For fiscal year 2024, Kenvue reported net sales of $15.5 billion with organic sales growth of 1.5%. The company employs approximately 22,000 people globally and maintains a market capitalization of approximately $31 billion as of late 2025. ### Who leads Kenvue? Kirk Perry serves as Chief Executive Officer of Kenvue, having assumed the role permanently in November 2025 after serving as Interim CEO since July 2025. Amit Banati serves as Chief Financial Officer, joining from Kellanova in May 2025. Together they lead the company through its strategic review and pending Kimberly-Clark acquisition. ### What makes Kenvue different from competitors? Kenvue differentiates itself through its portfolio of iconic, multi-generational brands with deep consumer trust, strong relationships with healthcare professionals who recommend its products, science-backed product development with significant R&D investment, and over 135 years of consumer health expertise inherited from Johnson & Johnson. ### Is Kenvue hiring? Kenvue actively recruits talent globally across research & development, marketing, sales, operations, and corporate functions. The company offers competitive benefits including a 9% 401k match, flexible work arrangements, comprehensive health insurance, and robust professional development opportunities through its Learning at Kenvue platform. ## Tags b2c, global, healthtech, manufacturing, public, retailtech --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*